Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
Journal of Opioid Management|October 29, 2021
Multimodal opioid sparing onco-anesthesia: A consensus practice guideline from Society of Onco-Anesthesia and Perioperative Care (SOAPC)Sohan Lal Solanki, Raghu S Thota, Jeson Rajan, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Blood|June 13, 2012
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaYu-Tzu Tai, Betty Y Chang, Sun-Young Kong, et al.
Cancer Cell|June 16, 2012
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphomaYibin Yang, Arthur L Shaffer, N C Tolga Emre, et al.
Structure (London, England : 1993)|July 10, 2004
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylasesJohn R Somoza, Robert J Skene, Bradley A Katz, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
British Journal of Anaesthesia|February 9, 2024
Pathological findings associated with the updated European Society of Cardiology 2022 guidelines for preoperative cardiac testing: an observational cohort modelling studyAlexandra Stroda, Eckhard Mauermann, Daniela Ionescu, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMichael L Wang, Simon Rule, Peter Martin, et al.
Pageof 21